Nalaganje...
A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis
BACKGROUND: Accumulation of toxic free cholesterol in hepatocytes may cause hepatic inflammation and fibrosis. Volixibat inhibits bile acid reuptake via the apical sodium bile acid transporter located on the luminal surface of the ileum. The resulting increase in bile acid synthesis from cholesterol...
Shranjeno v:
| izdano v: | BMC Pharmacol Toxicol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5857122/ https://ncbi.nlm.nih.gov/pubmed/29548345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-018-0200-y |
| Oznake: |
Označite
Brez oznak, prvi označite!
|